The Carter Center has estimated that the addiction crisis in the United States (US), if continues to worsen at the same rate, may cost the country approximately 16 trillion dollars by 2030. In recent years, the well-being of youth has been compromised by not only the coronavirus disease 2019 pandemic but also the alarming global opioid crisis, particularly in the US. Each year, deadly opioid drugs claim hundreds of thousands of lives, contributing to an ever-rising death toll. In addition, maternal usage of opioids and other drugs during pregnancy could compromise the neurodevelopment of children. A high rate of DNA polymorphic antecedents compounds the occurrence of epigenetic insults involving methylation of specific essential genes related to normal brain function. These genetic antecedent insults affect healthy DNA and mRNA transcription, leading to a loss of proteins required for normal brain development and function in youth. Myelination in the frontal cortex, a process known to extend until the late 20s, delays the development of proficient executive function and decision-making abilities. Understanding this delay in brain development, along with the presence of potential high-risk antecedent polymorphic variants or alleles and generational epigenetics, provides a clear rationale for embracing the Brain Research Commission’s suggestion to mimic fitness programs with an adaptable brain health check (BHC). Implementing the BHC within the educational systems in the US and other countries could serve as an effective initiative for proactive therapies aimed at reducing juvenile mental health problems and eventually criminal activities, addiction, and other behaviors associated with reward deficiency syndrome.

1. Miller M, Chen ALC, Stokes SD, et al. Early intervention of intravenous KB220IV--neuroadaptagen amino-acid therapy (NAAT) improves behavioral outcomes in a residential addiction treatment program: A pilot study. J Psychoactive Drugs. 2012;44(5):398-409. doi: 10.1080/02791072.2012.737727

2. Miller DK, Bowirrat A, Manka M, et al. Acute intravenous synaptamine complex variant KB220™ “normalizes” neurological dysregulation in patients during protracted abstinence from alcohol and opiates as observed using quantitative electroencephalographic and genetic analysis for reward polymorphisms: Part 1, pilot study with 2 case reports. Postgrad Med. 2010;122(6):188-213. doi: 10.3810/pgm.2010.11.2236

3. Blum K, Chen TJH, Downs BW, et al. Synaptamine (SG8839) an amino-acid enkephalinase inhibition nutraceutical improves recovery of alcoholics, a subtype of reward deficiency syndrome (RDS). Trends Appl Sci Res. 2007;2(2):132-138.

4. Blum K, Liu Y, Wang W, et al. rsfMRI effects of KB220Z™ on neural pathways in reward circuitry of abstinent genotyped heroin addicts. Postgrad Med. 2015;127(2):232-241. doi: 10.1080/00325481.2015.994879

5. Blum K, Chen AL, Chen TJ, et al. Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): A commentary. Theor Biol Med Model. 2008;5:24. doi: 10.1186/1742-4682-5-24

6. Gold MS, Baron D, Bowirrat A, Blum K. Neurological correlates of brain reward circuitry linked to opioid use disorder (OUD): Do homo sapiens acquire or have a reward deficiency syndrome? J Neurol Sci. 2020;418:117137. doi: 10.1016/j.jns.2020.117137

7. Martins SS, Sampson L, Cerdá M, Galea S. Worldwide prevalence and trends in unintentional drug overdose: A systematic review of the literature. Am J Public Health. 2015;105(11):e29-e49. doi: 10.2105/AJPH.2015.302843

8. Thorpe HHA, Hamidullah S, Jenkins BW, Khokhar JY. Adolescent neurodevelopment and substance use: Receptor expression and behavioral consequences. Pharmacol Ther. 2020;206:107431. doi: 10.1016/j.pharmthera.2019.107431

9. Strulik H. Opioid epidemics. Econ Hum Biol. 2020;37:100835. doi: 10.1016/j.ehb.2019.100835

10. Horseman C, Meyer A. Neurobiology of addiction. Clin Obstet Gynecol. 2019;62(1):118-127. doi: 10.1097/GRF.0000000000000416

11. Blum K, Modestino EJ, Badgaiyan RD, et al. Analysis of evidence for the combination of pro-dopamine regulator (KB220PAM) and naltrexone to prevent opioid use disorder relapse. EC Psychol Psychiatr. 2018;7(8):564-579.

12. Morgan JR, Schackman BR, Leff JA, Linas BP, Walley AY. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. J Subst Abuse Treat. 2018;85:90-96. doi: 10.1016/j.jsat.2017.07.001

13. Daoust M, Legrand E, Gewiss M, et al. Acamprosate modulates synaptosomal GABA transmission in chronically alcoholised rats. Pharmacol Biochem Behav. 1992;41(4):669-674. doi: 10.1016/0091-3057(92)90210-7

14. Blum K, Baron D, Lott L, et al. In search of reward deficiency syndrome (RDS)-free controls: The “Holy Grail” in genetic addiction risk testing. Curr Psychopharmacol. 2020;9(1):7-21.

15. Baron D, Blum K, Chen A, Gold M, Badgaiyan RD. Conceptualizing addiction from an osteopathic perspective: Dopamine homeostasis. J Am Osteopath Assoc. 2018;118(2):115-118. doi: 10.7556/jaoa.2018.026

16. Blum K, Modestino EJ, Gondré-Lewis M, et al. “Dopamine homeostasis” requires balanced polypharmacy: Issue with destructive, powerful dopamine agents to combat America’s drug epidemic. J Syst Integr Neurosci. 2017;3(6). doi: 10.15761/JSIN.1000183

17. Kenneth B, Edward MJ, Marjorie GLC, et al. Pro-dopamine regulator (KB220) a fifty year sojourn to combat reward deficiency syndrome (RDS): Evidence based Bibliography (Annotated). CPQ Neurol Psychol. 2018;1:2.

18. Febo M, Blum K, Badgaiyan RD, et al. Enhanced functional connectivity and volume between cognitive and reward centers of naïve rodent brain produced by pro-dopaminergic agent KB220Z. PLoS One. 2017;12(4):e0174774. doi: 10.1371/journal.pone.0174774

19. Blum K, Chen ALC, Thanos PK, et al. Genetic addiction risk score (GARS)™, a predictor of vulnerability to opioid dependence. Front Biosci (Elite Ed). 2018;10(1):175-196. doi: 10.2741/e816

20. Gold MS, Blum K, Febo M, et al. Molecular role of dopamine in anhedonia linked to reward deficiency syndrome (RDS) and anti- reward systems. Front Biosci (Schol Ed). 2018;10(2):309-325. doi: 10.2741/s518

21. Blum K, Modestino EJ, Gondre-Lewis M, et al. The benefits of genetic addiction risk score (GARS™) testing in substance use disorder (SUD). Int J Genom Data Min. 2018;2018(1):115. doi: 10.29014/IJGD-115.000015

22. Blum K, Thanos PK, Wang GJ, et al. The food and drug addiction epidemic: Targeting dopamine homeostasis. Curr Pharm Des. 2018;23(39):6050-6061. doi: 10.2174/1381612823666170823101713

23. Blum K, Badgaiyan RD, Braverman ER, et al. Hypothesizing that, A pro-dopamine regulator (KB220Z) should optimize, but not hyper-activate the activity of trace amine-associated receptor 1 (TAAR-1) and induce anti-craving of psychostimulants in the long-term. J Reward Defic Syndr Addict Sci. 2016;2(1):14-21. doi: 10.17756/jrdsas.2016-023

24. Blum K, Modestino EJ, Neary J, et al. Promoting precision addiction management (PAM) to combat the global opioid crisis. Biomed J Sci Tech Res. 2018;2(2):1-4. doi: 10.26717/BJSTR.2018.02.000738

25. Blum K, Gondré-Lewis MC, Baron D, et al. Introducing precision addiction management of reward deficiency syndrome, the construct that underpins all addictive behaviors. Front Psychiatry. 2018;9:548. doi: 10.3389/fpsyt.2018.00548

26. Volkow ND. Toward individualized treatment for substance abuse. Addict Sci Clin Pract. 2010;5(2):2.

27. Blum K, Baron D, McLaughlin T, Gold MS. Molecular neurological correlates of endorphinergic/dopaminergic mechanisms in reward circuitry linked to endorphinergic deficiency syndrome (EDS). J Neurol Sci. 2020;411:116733. doi: 10.1016/j.jns.2020.116733

28. Rosen GD, Chesler EJ, Manly KF, Williams RW. An informatics approach to systems neurogenetics. Methods Mol Biol. 2007;401:287-303. doi: 10.1007/978-1-59745-520-6_16

29. Blum K, Febo M, Smith DE, et al. Neurogenetic and epigenetic correlates of adolescent predisposition to and risk for addictive behaviors as a function of prefrontal cortex dysregulation. J Child Adolesc Psychopharmacol. 2015;25(4):286-292. doi: 10.1089/cap.2014.0146

30. Blum K, Bowirrat A, Gondre Lewis MC, et al. Exploration of epigenetic state hyperdopaminergia (Surfeit) and genetic trait hypodopaminergia (Deficit) during adolescent brain development. Curr Psychopharmacol. 2021;10:181-196. doi: 10.2174/2211556010666210215155509

31. Blum K, Febo M, McLaughlin T, Cronjé FJ, Han D, Gold SM. Hatching the behavioral addiction egg: Reward deficiency solution system (RDSS)™ as a function of dopaminergic neurogenetics and brain functional connectivity linking all addictions under a common rubric. J Behav Addict. 2014;3(3):149-156. doi: 10.1556/JBA.3.2014.019

32. Mackey S, Stewart JL, Connolly CG, Tapert SF, Paulus MP. A voxel-based morphometry study of young occasional users of amphetamine-type stimulants and cocaine. Drug Alcohol Depend. 2014;135:104-111. doi: 10.1016/j.drugalcdep.2013.11.018

33. Pfefferbaum A, Mathalon DH, Sullivan EV, Rawles JM, Zipursky RB, Lim KO. A quantitative magnetic resonance imaging study of changes in brain morphology from infancy to late adulthood. Arch Neurol. 1994;51(9):874-887. doi: 10.1001/archneur.1994.00540210046012

34. Giedd JN, Rumsey JM, Castellanos FX, et al. A quantitative MRI study of the corpus callosum in children and adolescents. Brain Res Dev Brain Res. 1996;91(2):274-280. doi: 10.1016/0165-3806(95)00193-x

35. Spear L. Modeling adolescent development and alcohol use in animals. Alcohol Res Health. 2000;24(2):115-123.

36. Yurgelun-Todd DA, Killgore WD, Young AD. Sex differences in cerebral tissue volume and cognitive performance during adolescence. Psychol Rep. 2002;91(3 Pt 1):743-757. doi: 10.2466/pr0.2002.91.3.743

37. Melo P, Moreno VZ, Vázquez SP, Pinazo-Durán MD, Tavares MA. Myelination changes in the rat optic nerve after prenatal exposure to methamphetamine. Brain Res. 2006;1106(1):21-29. doi: 10.1016/j.brainres.2006.05.020

38. Xu J, Yang B, Yan C, et al. Effects of duration and timing of prenatal stress on hippocampal myelination and synaptophysin expression. Brain Res. 2013;1527:57-66. doi: 10.1016/j.brainres.2013.06.025

39. De Bellis MD, Narasimhan A, Thatcher DL, Keshavan MS, Soloff P, Clark DB. Prefrontal cortex, thalamus, and cerebellar volumes in adolescents and young adults with adolescent-onset alcohol use disorders and comorbid mental disorders. Alcohol Clin Exp Res. 2005;29(9):1590-1600. doi: 10.1097/01.alc.0000179368.87886.76

40. Kofink D, Boks MPM, Timmers HT, Kas MJ. Epigenetic dynamics in psychiatric disorders: Environmental programming of neurodevelopmental processes. Neurosci Biobehav Rev. 2013;37(5):831-845. doi: 10.1016/j.neubiorev.2013.03.020

41. Volkow ND, Baler RD. NOW vs LATER brain circuits: Implications for obesity and addiction. Trends Neurosci. 2015;38(6):345-352. doi: 10.1016/j.tins.2015.04.002

42. Dalterio S, Blum K, DeLallo L, Sweeney C, Briggs A, Bartke A. Perinatal exposure to delta 9-THC in mice: Altered enkephalin and norepinephrine sensitivity in vas deferens. Subst Alcohol Actions Misuse. 1980;1(5-6):467-471.

43. Hagerty SL, YorkWilliams SL, Bidwell LC, et al. DRD2 methylation is associated with executive control network connectivity and severity of alcohol problems among a sample of polysubstance users. Addict Biol. 2020;25(1):e12684. doi: 10.1111/adb.12684

44. Hillemacher T, Rhein M, Burkert A, et al. DNA-methylation of the dopamin receptor 2 gene is altered during alcohol withdrawal. Eur Neuropsychopharmacol. 2019;29(11):1250-1257. doi: 10.1016/j.euroneuro.2019.09.002

45. Groleau P, Joober R, Israel M, Zeramdini N, DeGuzman R, Steiger H. Methylation of the dopamine D2 receptor (DRD2) gene promoter in women with a bulimia-spectrum disorder: Associations with borderline personality disorder and exposure to childhood abuse. J Psychiatr Res. 2014;48(1):121-127. doi: 10.1016/j.jpsychires.2013.10.003

46. Hillemacher T, Frieling H, Buchholz V, et al. Alterations in DNA-methylation of the dopamine-receptor 2 gene are associated with abstinence and health care utilization in individuals with a lifetime history of pathologic gambling. Prog Neuropsychopharmacol Biol Psychiatry. 2015;63:30-34. doi: 10.1016/j.pnpbp.2015.05.013

47. Staes N, White CM, Guevara EE, et al. Chimpanzee Extraversion scores vary with epigenetic modification of dopamine receptor gene D2 (DRD2) and early rearing conditions. Epigenetics. 2022;17(12):1701-1714. doi: 10.1080/15592294.2022.2058224

48. Frieling H, Römer KD, Scholz S, et al. Epigenetic dysregulation of dopaminergic genes in eating disorders. Int J Eat Disord. 2010;43(7):577-583. doi: 10.1002/eat.20745

49. Zhang J, Fan Y, Zhou J, et al. Methylation quantitative trait locus rs5326 is associated with susceptibility and effective dosage of methadone maintenance treatment for heroin use disorder. Psychopharmacology (Berl). 2021;238(12):3511-3518. doi: 10.1007/s00213-021-05968-8

50. Nohesara S, Ghadirivasfi M, Barati M, et al. Methamphetamine-induced psychosis is associated with DNA hypomethylation and increased expression of AKT1 and key dopaminergic genes. Am J Med Genet B Neuropsychiatr Genet. 2016;171(8):1180-1189. doi: 10.1002/ajmg.b.32506

51. Feltmann K, Borroto-Escuela DO, Rüegg J, et al. Effects of long-term alcohol drinking on the dopamine D2 receptor: Gene expression and heteroreceptor complexes in the striatum in rats. Alcohol Clin Exp Res. 2018;42(2):338-351. doi: 10.1111/acer.13568

52. Hill SY, Sharma VK. DRD2 methylation and regional grey matter volumes in young adult offspring from families at ultra-high risk for alcohol dependence. Psychiatry Res Neuroimaging. 2019;286:31-38. doi: 10.1016/j.pscychresns.2019.03.006

53. Klaus K, Vaht M, Pennington K, Harro J. Interactive effects of DRD2 rs6277 polymorphism, environment and sex on impulsivity in a population-representative study. Behav Brain Res. 2021;403:113131. doi: 10.1016/j.bbr.2021.113131

54. Bidwell LC, Karoly HC, Thayer RE, et al. DRD2 promoter methylation and measures of alcohol reward: Functional activation of reward circuits and clinical severity. Addict Biol. 2019;24(3):539-548. doi: 10.1111/adb.12614

55. Pandey SC, Kyzar EJ, Zhang H. Epigenetic basis of the dark side of alcohol addiction. Neuropharmacology. 2017;122:74-84. doi: 10.1016/j.neuropharm.2017.02.002

56. Liu Q, Xu Y, Mao Y, et al. Genetic and epigenetic analysis revealing variants in the NCAM1-TTC12-ANKK1-DRD2 cluster associated significantly with nicotine dependence in Chinese Han smokers. Nicotine Tob Res. 2020;22(8):1301-1309. doi: 10.1093/ntr/ntz240

57. Modestino EJ, Blum K, Oscar-Berman M, et al. Reward deficiency syndrome: Attentional/arousal subtypes, limitations of current diagnostic nosology, and future research. J Reward Defic Syndr. 2015;1(1):6-9. doi: 10.17756/jrds.2015-002

58. Yamasue H, Domes G. Oxytocin and autism spectrum disorders. Curr Top Behav Neurosci. 2018;35:449-465. doi: 10.1007/7854_2017_24

59. Lindgren E, Gray K, Miller G, et al. Food addiction: A common neurobiological mechanism with drug abuse. Front Biosci (Landmark Ed). 2018;23(5):811-836. doi: 10.2741/4618

60. Rodriguez-Moreno DV, Cycowicz YM, Figner B, et al. Delay discounting and neurocognitive correlates among inner city adolescents with and without family history of substance use disorder. Dev Cogn Neurosci. 2021;48:100942. doi: 10.1016/j.dcn.2021.100942

61. Steinberg L. A social neuroscience perspective on adolescent risk-taking. Dev Rev. 2008;28(1):78-106. doi: 10.1016/j.dr.2007.08.002

62. Casey BJ, Jones RM. Neurobiology of the adolescent brain and behavior: Implications for substance use disorders. J Am Acad Child Adolesc Psychiatry. 2010;49(12):1189-1285. doi: 10.1016/j.jaac.2010.08.017

63. Casey BJ, Jones RM, Hare TA. The adolescent brain. Ann N Y Acad Sci. 2008;1124:111-126. doi: 10.1196/annals.1440.010

64. Somerville LH, Hare T, Casey BJ. Frontostriatal maturation predicts cognitive control failure to appetitive cues in adolescents. J Cogn Neurosci. 2011;23(9):2123-2134. doi: 10.1162/jocn.2010.21572

65. Christakou A, Brammer M, Rubia K. Maturation of limbic corticostriatal activation and connectivity associated with developmental changes in temporal discounting. Neuroimage. 2011;54(2):1344-1354. doi: 10.1016/j.neuroimage.2010.08.067

66. Christakou A, Brammer M, Giampietro V, Rubia K. Right ventromedial and dorsolateral prefrontal cortices mediate adaptive decisions under ambiguity by integrating choice utility and outcome evaluation. J Neurosci. 2009;29(35):11020-11028. doi: 10.1523/JNEUROSCI.1279-09.2009

67. Ripke S, Hübner T, Mennigen E, et al. Reward processing and intertemporal decision making in adults and adolescents: The role of impulsivity and decision consistency. Brain Res. 2012;1478:36-47. doi: 10.1016/j.brainres.2012.08.034

68. de Water E, Cillessen AH, Scheres A. Distinct age-related differences in temporal discounting and risk taking in adolescents and young adults. Child Dev. 2014;85(5):1881-1897. doi: 10.1111/cdev.12245

69. Steinberg L, Graham S, O’Brien L, Woolard J, Cauffman E, Banich M. Age differences in future orientation and delay discounting [published correction appears in Child Dev. 2010;81(3):1024]. Child Dev. 2009;80(1):28-44. doi: 10.1111/j.1467-8624.2008.01244.x

70. Aytaclar S, Tarter RE, Kirisci L, Lu S. Association between hyperactivity and executive cognitive functioning in childhood and substance use in early adolescence. J Am Acad Child Adolesc Psychiatry. 1999;38(2):172-178. doi: 10.1097/00004583-199902000-00016

71. Brancato A, Castelli V, Lavanco G, Marino RAM, Cannizzaro C. In utero Δ9-tetrahydrocannabinol exposure confers vulnerability towards cognitive impairments and alcohol drinking in the adolescent offspring: Is there a role for neuropeptide Y? J Psychopharmacol. 2020;34(6):663-679. doi: 10.1177/0269881120916135

72. Wozniak JR, Riley EP, Charness ME. Clinical presentation, diagnosis, and management of fetal alcohol spectrum disorder. Lancet Neurol. 2019;18(8):760-770. doi: 10.1016/S1474-4422(19)30150-4

73. Beecher K, Alvarez Cooper I, Wang J, et al. Long-term overconsumption of sugar starting at adolescence produces persistent hyperactivity and neurocognitive deficits in adulthood. Front Neurosci. 2021;15:670430. doi: 10.3389/fnins.2021.670430

74. Bihlar Muld B, Jokinen J, Bölte S, Hirvikoski T. Attention deficit/hyperactivity disorders with co-existing substance use disorder is characterized by early antisocial behaviour and poor cognitive skills. BMC Psychiatry. 2013;13:336. doi: 10.1186/1471-244X-13-336

75. Boggess T, Risher WC. Clinical and basic research investigations into the long-term effects of prenatal opioid exposure on brain development. J Neurosci Res. 2022;100(1):396-409. doi: 10.1002/jnr.24642

76. Wiss DA, Avena N, Rada P. Sugar addiction: From evolution to revolution. Front Psychiatry. 2018;9:545. doi: 10.3389/fpsyt.2018.00545

77. Levey DF, Stein MB, Wendt FR, et al. Bi-ancestral depression GWAS in the million veteran program and meta-analysis in >1.2 million individuals highlight new therapeutic directions. Nat Neurosci. 2021;24(7):954-963. doi: 10.1038/s41593-021-00860-2

78. Chaput JP, Willumsen J, Bull F, et al. 2020 WHO guidelines on physical activity and sedentary behaviour for children and adolescents aged 5-17 years: Summary of the evidence. Int J Behav Nutr Phys Act. 2020;17(1):141. doi: 10.1186/s12966-020-01037-z

79. Robison LS, Swenson S, Hamilton J, Thanos PK. Exercise reduces dopamine D1R and increases D2R in rats: Implications for addiction. Med Sci Sports Exerc. 2018;50(8):1596-1602. doi: 10.1249/MSS.0000000000001627

80. Swenson S, Blum K, McLaughlin T, Gold MS, Thanos PK. The therapeutic potential of exercise for neuropsychiatric diseases: A review. J Neurol Sci. 2020;412:116763. doi: 10.1016/j.jns.2020.116763

81. Blum K, Gondré-Lewis MC, Modestino EJ, et al. Understanding the scientific basis of post-traumatic stress disorder (PTSD): Precision behavioral management overrides stigmatization. Mol Neurobiol. 2019;56(11):7836-7850. doi: 10.1007/s12035-019-1600-8

82. Weimer DL, Moberg P, French F, Tanner-Smith EE, Finch AJ. Net benefits of recovery high schools: Higher cost but increased sobriety and educational attainment. J Ment Health Policy Econ. 2019;22(3):109-120.

83. Tanner-Smith EE, Nichols LM, Loan CM, Finch AJ, Moberg DP. Recovery high school attendance effects on student delinquency and substance use: The moderating role of social problem solving styles. Prev Sci. 2020;21(8):1104-1113. doi: 10.1007/s11121-020-01161-z

84. Nami M, Thatcher R, Kashou N, et al. A proposed brain-, spine-, and mental- health screening methodology (NEUROSCREEN) for healthcare systems: Position of the society for brain mapping and therapeutics. J Alzheimers Dis. 2022;86(1):21-42. doi: 10.3233/JAD-215240

85. Hammond CJ, Mayes LC, Potenza MN. Neurobiology of adolescent substance use and addictive behaviors: Treatment implications. Adolesc Med State Art Rev. 2014;25(1):15-32.

86. Braverman ER, Dennen CA, Gold MS, et al. Proposing a “brain health checkup (BHC)” as a global potential “standard of care” to overcome reward dysregulation in primary care medicine: Coupling genetic risk testing and induction of “dopamine homeostasis”. Int J Environ Res Public Health. 2022;19(9):5480. doi: 10.3390/ijerph19095480

87. Ostby Y, Tamnes CK, Fjell AM, Westlye LT, Due- Tønnessen P, Walhovd KB. Heterogeneity in subcortical brain development: A structural magnetic resonance imaging study of brain maturation from 8 to 30 years. J Neurosci. 2009;29(38):11772-11782. doi: 10.1523/JNEUROSCI.1242-09.2009

88. Gogtay N, Thompson PM. Mapping gray matter development: Implications for typical development and vulnerability to psychopathology. Brain Cogn. 2010;72(1):6-15. doi: 10.1016/j.bandc.2009.08.009

89. Paus T. Growth of white matter in the adolescent brain: Myelin or axon? Brain Cogn. 2010;72(1):26-35. doi: 10.1016/j.bandc.2009.06.00

90. Giedd JN, Blumenthal J, Jeffries NO, et al. Brain development during childhood and adolescence: A longitudinal MRI study. Nat Neurosci. 1999;2(10):861-863. doi: 10.1038/13158

91. Sowell ER, Thompson PM, Holmes CJ, Batth R, Jernigan TL, Toga AW. Localizing age-related changes in brain structure between childhood and adolescence using statistical parametric mapping. Neuroimage. 1999;9(6 Pt 1):587-597. doi: 10.1006/nimg.1999.0436

92. Gogtay N, Giedd JN, Lusk L, et al. Dynamic mapping of human cortical development during childhood through early adulthood. Proc Natl Acad Sci U S A. 2004;101(21):8174-8179. doi: 10.1073/pnas.0402680101

93. Smith SS. α4βδ GABAA receptors and tonic inhibitory current during adolescence: Effects on mood and synaptic plasticity. Front Neural Circuits. 2013;7:135. doi: 10.3389/fncir.2013.00135

94. Blum K, McLaughlin T, Bowirrat A, et al. Reward deficiency syndrome (RDS) surprisingly is evolutionary and found everywhere: Is it “blowin’ in the wind”? J Pers Med. 2022;12(2):321. doi: 10.3390/jpm12020321

95. Monaco AP. An epigenetic, transgenerational model of increased mental health disorders in children, adolescents and young adults. Eur J Hum Genet. 2021;29(3):387-395. doi: 10.1038/s41431-020-00726-4

96. Spano MS, Ellgren M, Wang X, Hurd YL. Prenatal cannabis exposure increases heroin seeking with allostatic changes in limbic enkephalin systems in adulthood. Biol Psychiatry. 2007;61(4):554-563. doi: 10.1016/j.biopsych.2006.03.073

97. Yuan M, Cross SJ, Loughlin SE, Leslie FM. Nicotine and the adolescent brain. J Physiol. 2015;593(16):3397-3412. doi: 10.1113/JP270492

98. Slotkin TA, Seidler FJ. Nicotine exposure in adolescence alters the response of serotonin systems to nicotine administered subsequently in adulthood. Dev Neurosci. 2009;31(1-2):58-70. doi: 10.1159/000207494

99. Tseng KY, O’Donnell P. D2 dopamine receptors recruit a GABA component for their attenuation of excitatory synaptic transmission in the adult rat prefrontal cortex. Synapse. 2007;61(10):843-850. doi: 10.1002/syn.20432

100. O’Donnell P. Adolescent maturation of cortical dopamine. Neurotox Res. 2010;18(3-4):306-312. doi: 10.1007/s12640-010-9157-3

101. Flores-Barrera E, Thomases DR, Heng LJ, Cass DK, Caballero A, Tseng KY. Late adolescent expression of GluN2B transmission in the prefrontal cortex is input-specific and requires postsynaptic protein kinase A and D1 dopamine receptor signaling. Biol Psychiatry. 2014;75(6):508-516. doi: 10.1016/j.biopsych.2013.07.033

102. Benoit-Marand M, O’Donnell P. D2 dopamine modulation of corticoaccumbens synaptic responses changes during adolescence. Eur J Neurosci. 2008;27(6):1364-1372. doi: 10.1111/j.1460-9568.2008.06107.x

103. Huppé-Gourgues F, O’Donnell P. D₁-NMDA receptor interactions in the rat nucleus accumbens change during adolescence. Synapse. 2012;66(7):584-591. doi: 10.1002/syn.21544

104. You C, Vandegrift BJ, Zhang H, Lasek AW, Pandey SC, Brodie MS. Histone deacetylase inhibitor suberanilohydroxamic acid treatment reverses hyposensitivity to γ-aminobutyric acid in the ventral tegmental area during ethanol withdrawal. Alcohol Clin Exp Res. 2018;42(11):2160-2171. doi: 10.1111/acer.13870

105. Mueller AL, Brodie MS. Intracellular recording from putative dopamine-containing neurons in the ventral tegmental area of Tsai in a brain slice preparation. J Neurosci Methods. 1989;28(1-2):15-22. doi: 10.1016/0165-0270(89)90005-8

106. Arora DS, Nimitvilai S, Teppen TL, et al. Hyposensitivity to gamma-aminobutyric acid in the ventral tegmental area during alcohol withdrawal: Reversal by histone deacetylase inhibitors. Neuropsychopharmacology. 2013;38(9):1674-1684. doi: 10.1038/npp.2013.65

107. Jacob KS, Patel V. Classification of mental disorders: A global mental health perspective. Lancet. 2014;383(9926):1433-1435. doi: 10.1016/S0140-6736(13)62382-X

108. Casey BJ, Craddock N, Cuthbert BN, Hyman SE, Lee FS, Ressler KJ. DSM-5 and RDoC: Progress in psychiatry research? Nat Rev Neurosci. 2013;14(11):810-814. doi: 10.1038/nrn3621

109. Seligman MEP. The Optimistic Child: A Proven Program to Safeguard Children against Depression and Build Lifelong Resilience. Boston: Houghton Mifflin Harcourt; 2007.

110. Domitrovich CE, Durlak JA, Staley KC, Weissberg RP. Social-emotional competence: An essential factor for promoting positive adjustment and reducing risk in school children. Child Dev. 2017;88(2):408-416. doi: 10.1111/cdev.12739

111. Ciocanel O, Power K, Eriksen A, Gillings K. Effectiveness of positive youth development interventions: A meta-analysis of randomized controlled trials. J Youth Adolesc. 2017;46(3):483-504. doi: 10.1007/s10964-016-0555-6

112. Benoit V, Gabola P. Effects of positive psychology interventions on the well-being of young children: A systematic literature review. Int J Environ Res Public Health. 2021;18(22):12065. doi: 10.3390/ijerph182212065

113. Young KS, Sandman CF, Craske MG. Positive and negative emotion regulation in adolescence: Links to anxiety and depression. Brain Sci. 2019;9(4):76. doi: 10.3390/brainsci9040076

114. Straube T, Sauer A, Miltner WH. Brain activation during direct and indirect processing of positive and negative words. Behav Brain Res. 2011;222(1):66-72. doi: 10.1016/j.bbr.2011.03.037

115. Hong YJ, Park S, Kyeong S, Kim JJ. Neural basis of professional pride in the reaction to uniform wear. Front Hum Neurosci. 2019;13:253. doi: 10.3389/fnhum.2019.00253

116. Berridge KC, Kringelbach ML. Pleasure systems in the brain. Neuron. 2015;86(3):646-664. doi: 10.1016/j.neuron.2015.02.018

117. Volkow ND, Tomasi D, Wang GJ, et al. Positive emotionality is associated with baseline metabolism in orbitofrontal cortex and in regions of the default network. Mol Psychiatry. 2011;16(8):818-825. doi: 10.1038/mp.2011.30

118. Blum K, Merritt JH, Wallace JE, Owen R, Hahn JW, Geller I. Effects of catecholamine synthesis inhibition on ethanol narcosis in mice. Curr Ther Res Clin Exp. 1972;14(6):324-329.

119. Dackis CA, Gold MS. New concepts in cocaine addiction: The dopamine depletion hypothesis. Neurosci Biobehav Rev. 1985;9(3):469-477. doi: 10.1016/0149-7634(85)90022-3

120. Selvaraj S, Mouchlianitis E, Faulkner P, et al. Presynaptic serotoninergic regulation of emotional processing: A multimodal brain imaging study. Biol Psychiatry. 2015;78(8):563-571. doi: 10.1016/j.biopsych.2014.04.011

121. Chen X, Gautam P, Haroon E, Rilling JK. Within vs. Between-subject effects of intranasal oxytocin on the neural response to cooperative and non-cooperative social interactions. Psychoneuroendocrinology. 2017;78:22-30. doi: 10.1016/j.psyneuen.2017.01.006

122. Ashford JW, Tarpin-Bernard F, Ashford CB, Ashford MT. A computerized continuous-recognition task for measurement of episodic memory. J Alzheimers Dis. 2019;69(2):385-399. doi: 10.3233/JAD-190167

123. Liu X, Chen X, Zhou X, et al. Validity of the memtrax memory test compared to the Montreal cognitive assessment in the detection of mild cognitive impairment and dementia due to Alzheimer’s disease in a Chinese cohort. J Alzheimers Dis. 2021;80(3):1257-1267. doi: 10.3233/JAD-200936

124. van der Hoek MD, Nieuwenhuizen A, Keijer J, Ashford JW. The MemTrax test compared to the Montreal cognitive assessment estimation of mild cognitive impairment. J Alzheimers Dis. 2019;67(3):1045-1054. doi: 10.3233/JAD-181003

125. Gualtieri CT, Johnson LG. Reliability and validity of a computerized neurocognitive test battery, CNS Vital Signs. Arch Clin Neuropsychol. 2006;21(7):623-643. doi: 10.1016/j.acn.2006.05.007

126. Campman C, van Ranst D, Meijer JW, Sitskoorn M. Computerized screening for cognitive impairment in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:3075-3083. doi: 10.2147/COPD.S142871

127. Olofsen E, Noppers I, Niesters M, et al. Estimation of the contribution of norketamine to ketamine-induced acute pain relief and neurocognitive impairment in healthy volunteers. Anesthesiology. 2012;117(2):353-364. doi: 10.1097/ALN.0b013e31825b6c91

128. Meador KJ, Seliger J, Boyd A, et al. Comparative neuropsychological effects of carbamazepine and eslicarbazepine acetate. Epilepsy Behav. 2019;94:151-157. doi: 10.1016/j.yebeh.2019.02.034

129. Littleton AC, Register-Mihalik JK, Guskiewicz KM. Test-retest reliability of a computerized concussion test: CNS vital signs. Sports Health. 2015;7(5):443-447. doi: 10.1177/1941738115586997

130. Brooks BL, Plourde V, Fay-McClymont TB, MacAllister WS, Sherman EMS. Factor structure of the CNS vital signs computerized cognitive battery in youth with neurological diagnoses. Child Neuropsychol. 2019;25(7):980-991. doi: 10.1080/09297049.2019.1569609

131. Braverman ER, Chen TJ, Schoolfield J, et al. Delayed P300 latency correlates with abnormal test of variables of attention (TOVA) in adults and predicts early cognitive decline in a clinical setting. Adv Ther. 2006;23(4):582-600. doi: 10.1007/BF02850047

132. Braverman ER, Chen AL, Chen TJ, et al. Test of variables of attention (TOVA) as a predictor of early attention complaints, an antecedent to dementia. Neuropsychiatr Dis Treat. 2010;6:681-690. doi: 10.2147/NDT.S12243

133. Bodkyn CN, Holroyd CB. Neural mechanisms of affective instability and cognitive control in substance use. Int J Psychophysiol. 2019;146:1-19. doi: 10.1016/j.ijpsycho.2019.08.003

134. Gruber R, Grizenko N, Schwartz G, Bellingham J, Guzman R, Joober R. Performance on the continuous performance test in children with ADHD is associated with sleep efficiency. Sleep. 2007;30(8):1003-1009. doi: 10.1093/sleep/30.8.1003

135. Rotem A, Danieli Y, Ben-Sheetrit J, et al. Apparent lack of practice effects in the test of variables of attention (TOVA) in adult ADHD. Atten Defic Hyperact Disord. 2019;11(1):73-81. doi: 10.1007/s12402-018-0278-5

136. Wojcik CM, Beier M, Costello K, et al. Computerized neuropsychological assessment devices in multiple sclerosis: A systematic review. Mult Scler. 2019;25(14):1848-1869. doi: 10.1177/1352458519879094

137. Lubar JF, Swartwood MO, Swartwood JN, O’Donnell PH. Evaluation of the effectiveness of EEG neurofeedback training for ADHD in a clinical setting as measured by changes in T.O.V.A. scores, behavioral ratings, and WISC-R performance. Biofeedback Self Regul. 1995;20(1):83-99. doi: 10.1007/BF01712768

138. Ball SA, Nich C, Rounsaville BJ, Eagan D, Carroll KM. Millon clinical multiaxial inventory-III subtypes of opioid dependence: Validity and matching to behavioral therapies. J Consult Clin Psychol. 2004;72(4):698-711. doi: 10.1037/0022-006X.72.4.698

139. Strack S, Millon T. Contributions to the dimensional assessment of personality disorders using Millon’s model and the Millon Clinical Multiaxial Inventory (MCMI9-III). J Pers Assess. 2007;89(1):56-69. doi: 10.1080/00223890701357217

140. Choca JP, Grossman SD. Evolution of the millon clinical multiaxial inventory. J Pers Assess. 2015;97(6):541-549. doi: 10.1080/00223891.2015.1055753

141. Blum K, Chen TJ, Morse S, et al. Overcoming qEEG abnormalities and reward gene deficits during protracted abstinence in male psychostimulant and polydrug abusers utilizing putative dopamine D₂ agonist therapy: Part 2. Postgrad Med. 2010;122(6):214-226. doi: 10.3810/pgm.2010.11.2237

142. Sokhadze TM, Cannon RL, Trudeau DL. EEG biofeedback as a treatment for substance use disorders: Review, rating of efficacy, and recommendations for further research. Appl Psychophysiol Biofeedback. 2008;33(1):1-28. doi: 10.1007/s10484-007-9047-5

143. van Dinteren R, Arns M, Jongsma ML, Kessels RP. P300 development across the lifespan: A systematic review and meta-analysis. PLoS One. 2014;9(2):e87347. doi: 10.1371/journal.pone.0087347

144. Braverman ER, Han D, Oscar-Berman M, et al. Menopause analytical hormonal correlate outcome study (MAHCOS) and the association to brain electrophysiology (P300) in a clinical setting. PLoS One. 2014;9(9):e105048. doi: 10.1371/journal.pone.0105048

145. Braverman ER, Blum K. P300 (latency) event-related potential: An accurate predictor of memory impairment. Clin Electroencephalogr. 2003;34(3):124-139. doi: 10.1177/155005940303400306

146. Braverman ER, Chen TJ, Chen AL, et al. Preliminary investigation of plasma levels of sex hormones and human growth factor(s), and P300 latency as correlates to cognitive decline as a function of gender. BMC Res Notes. 2009;2:126. doi: 10.1186/1756-0500-2-126

147. Wang GY, Kydd R, Russell BR. Resting EEG and ERPs findings in methadone-substituted opiate users: A review. Acta Neurol Belg. 2015;115(4):539-546. doi: 10.1007/s13760-015-0476-2

148. Porcaro C, Balsters JH, Mantini D, Robertson IH, Wenderoth N. P3b amplitude as a signature of cognitive decline in the older population: An EEG study enhanced by Functional Source Separation. Neuroimage. 2019;184:535-546. doi: 10.1016/j.neuroimage.2018.09.057

149. Campanella S, Pogarell O, Boutros N. Event-related potentials in substance use disorders: A narrative review based on articles from 1984 to 2012. Clin EEG Neurosci. 2014;45(2):67-76. doi: 10.1177/1550059413495533

150. Kalechstein AD, De la Garza R 2nd, Newton TF, Green MF, Cook IA, Leuchter AF. Quantitative EEG abnormalities are associated with memory impairment in recently abstinent methamphetamine-dependent individuals. J Neuropsychiatry Clin Neurosci. 2009;21(3):254-258. doi: 10.1176/jnp.2009.21.3.254

151. Bjørk MH, Sand T, Bråthen G, et al. Quantitative EEG findings in patients with acute, brief depression combined with other fluctuating psychiatric symptoms: A controlled study from an acute psychiatric department. BMC Psychiatry. 2008;8:89. doi: 10.1186/1471-244X-8-89

152. McVoy M, Lytle S, Fulchiero E, Aebi ME, Adeleye O, Sajatovic M. A systematic review of quantitative EEG as a possible biomarker in child psychiatric disorders. Psychiatry Res. 2019;279:331-344. doi: 10.1016/j.psychres.2019.07.004

153. Haghighi M, Ludyga S, Rahimi B, et al. In patients suffering from major depressive disorders, quantitative EEG showed favorable changes in left and right prefrontal cortex. Psychiatry Res. 2017;251:137-141. doi: 10.1016/j.psychres.2017.02.012

154. Gerez M, Tello A. Clinical significance of focal topographic changes in the electroencephalogram (EEG) and evoked potentials (EP) of psychiatric patients. Brain Topogr. 1992;5(1):3-10. doi: 10.1007/BF01129964

155. Rouhani N, Niv Y. Signed and unsigned reward prediction errors dynamically enhance learning and memory. Elife. 2021;10:e61077. doi: 10.7554/eLife.61077

156. Rouhani N, Norman KA, Niv Y. Dissociable effects of surprising rewards on learning and memory. J Exp Psychol Learn Mem Cogn. 2018;44(9):1430-1443. doi: 10.1037/xlm0000518

157. Katzman PL, Hartley CA. The value of choice facilitates subsequent memory across development. Cognition. 2020;199:104239. doi: 10.1016/j.cognition.2020.104239

158. Thanos PK, Tucci A, Stamos J, et al. Chronic forced exercise during adolescence decreases cocaine conditioned place preference in Lewis rats. Behav Brain Res. 2010;215(1):77-82. doi: 10.1016/j.bbr.2010.06.033

159. Dong GH, Wang Z, Dong H, et al. More stringent criteria are needed for diagnosing internet gaming disorder: Evidence from regional brain features and whole-brain functional connectivity multivariate pattern analyses. J Behav Addict. 2020;9(3):642-653. doi: 10.1556/2006.2020.00065

160. Ismail S, Odland ML, Malik A, et al. The relationship between psychosocial circumstances and injuries in adolescents: An analysis of 87,269 individuals from 26 countries using the Global School-based Student Health Survey. PLoS Med. 2021;18(9):e1003722. doi: 10.1371/journal.pmed.1003722

161. Kalindjian N, Hirot F, Stona AC, Huas C, Godart N. Early detection of eating disorders: A scoping review [published correction appears in Eat Weight Disord. 2021:]. Eat Weight Disord. 2022;27(1):21-68. doi: 10.1007/s40519-021-01164-x

162. Murthy P, Mahadevan J, Chand PK. Treatment of substance use disorders with co-occurring severe mental health disorders. Curr Opin Psychiatry. 2019;32(4):293-299. doi: 10.1097/YCO.0000000000000510

163. Dervaux A. Early detection and treatment of Alcohol dependence. Presse Med. 2018;47(6):532-534.

164. Crunelle CL, van den Brink W, Moggi F, et al. International consensus statement on screening, diagnosis and treatment of substance use disorder patients with comorbid attention deficit/ hyperactivity disorder. Eur Addict Res. 2018;24(1):43-51. doi: 10.1159/000487767168.

165. Bertulies-Esposito B, Sicotte R, Iyer SN, et al. Early detection and intervention for psychosis: Why and how? Sante Ment Que. 2021;46(2):45-83.

166. Gross M. Hepatic cirrhosis: Early diagnosis and prevention of complications. MMW Fortschr Med. 2019;161(7):48-52. doi: 10.1007/s15006-019-0408-9

167. Falissard B. Early detection of child and adolescent mental disorders: Some elements of a necessary debate. Eur Child Adolesc Psychiatry. 2016;25(10):1041-1043. doi: 10.1007/s00787-016-0906-6

168. Chan SY, Nickerson LD, Pathak R, Öngür D, Hall MH. Impact of substance use disorder on between-network brain connectivity in early psychosis. Schizophr Bull Open. 2022;3(1):sgac014. doi: 10.1093/schizbullopen/sgac014

169. Perugi G, Pallucchini A, Rizzato S, et al. Pharmacotherapeutic strategies for the treatment of attention-deficit hyperactivity (ADHD) disorder with comorbid substance-use disorder (SUD). Expert Opin Pharmacother. 2019;20(3):343-355. doi: 10.1080/14656566.2018.1551878

170. Fortier CB, Whitworth JW, Fonda JR, et al. Early adolescent binge drinking increases risk of psychopathology in post- 9/11 veterans and mild traumatic brain injury exacerbates symptom severity. Alcohol Alcohol. 2021;56(1):116-124. doi: 10.1093/alcalc/agaa075

171. Blanco C, Volkow ND. Management of opioid use disorder in the USA: Present status and future directions. Lancet. 2019;393(10182):1760-1772. doi: 10.1016/S0140-6736(18)33078-2

172. Beckmann D, Lowman KL, Nargiso J, McKowen J, Watt L, Yule AM. Substance-induced psychosis in youth. Child Adolesc Psychiatr Clin N Am. 2020;29(1):131-143. doi: 10.1016/j.chc.2019.08.006

173. Aly SM, Omran A, Gaulier JM, Allorge D. Substance abuse among children. Arch Pediatr. 2020;27(8):480-484. doi: 10.1016/j.arcped.2020.09.006

174. Lalli M, Brouillette K, Kapczinski F, de Azevedo Cardoso T. Substance use as a risk factor for bipolar disorder: A systematic review. J Psychiatr Res. 2021;144:285-295. doi: 10.1016/j.jpsychires.2021.10.012

175. Kong LZ, Chandimali N, Han YH, et al. Pathogenesis, early diagnosis, and therapeutic management of alcoholic liver disease. Int J Mol Sci. 2019;20(11):2712. doi: 10.3390/ijms20112712

176. Mondi CF, Giovanelli A, Ou SR, Reynolds AJ. Psychiatric and substance use disorders in a predominately low-income, black sample in early midlife. J Psychiatr Res. 2022;148:332-339. doi: 10.1016/j.jpsychires.2022.02.008

177. Duffy A, Horrocks J, Milin R, Doucette S, Persson G, Grof P. Adolescent substance use disorder during the early stages of bipolar disorder: A prospective high-risk study. J Affect Disord. 2012;142(1-3):57-64. doi: 10.1016/j.jad.2012.04.010

178. Benningfield MM, Riggs P, Stephan SH. The role of schools in substance use prevention and intervention. Child Adolesc Psychiatr Clin N Am. 2015;24(2):291-303. doi: 10.1016/j.chc.2014.12.004

179. Hawk KF, Glick RL, Jey AR, et al. Emergency medicine research priorities for early intervention for substance use disorders. West J Emerg Med. 2019;20(2):386-392. doi: 10.5811/westjem.2019.1.39261

180. González RA, Vélez-Pastrana MC, Blankers M, et al. Onset and severity of early disruptive behavioral disorders in treatment-seeking substance use disorder patients with and without attention-deficit/hyperactivity disorder. Eur Addict Res. 2020;26(4-5):211-222. doi: 10.1159/000508653

181. Kim Y, Kim K, Chartier KG, Wike TL, McDonald SE. Adverse childhood experience patterns, major depressive disorder, and substance use disorder in older adults. Aging Ment Health. 2021;25(3):484-491. doi: 10.1080/13607863.2019.1693974

182. Fuller-Thomson E, Lewis DA, Agbeyaka S. Attention-deficit/hyperactivity disorder and alcohol and other substance use disorders in young adulthood: Findings from a Canadian nationally representative survey. Alcohol Alcohol. 2022;57(3):385-395. doi: 10.1093/alcalc/agab048

183. Winters DE, Brandon-Friedman R, Yepes G, Hinckley JD. Systematic review and meta-analysis of socio-cognitive and socio-affective processes association with adolescent substance use. Drug Alcohol Depend. 2021;219:108479. doi: 10.1016/j.drugalcdep.2020.108479

184. Speed TJ, Hanks L, Turner G, et al. A comparison of cognitive behavioral therapy for insomnia to standard of care in an outpatient substance use disorder clinic embedded within a therapeutic community: A RE-AIM framework evaluation. Trials. 2022;23(1):965. doi: 10.1186/s13063-022-06885-7

185. Davis JP, Janssen T, Dworkin ER, Dumas TM, Goldbach J, Monterosso J. Influences of victimization and comorbid conditions on substance use disorder outcomes in justice-involved youth: A discrete time survival mixture analysis. Dev Psychopathol. 2020;32(3):1045-1058. doi: 10.1017/S0954579419000750

186. Veseth M, Svendsen TS, Nesvaag S, Moltu C, Davidson L, Bjornestad J. “And then the rest happened”- A qualitative exploration of the role that meaningful activities play in recovery processes for people with a diagnosis of substance use disorder. Subst Abus. 2022;43(1):260-266. doi: 10.1080/08897077.2021.1941506

187. Coetzee C, Schellekens AFA, Truter I, Meyer A. Effect of past pharmacotherapy for attention-deficit/hyperactivity disorder on substance use disorder. Eur Addict Res. 2023;29(1):9-18. doi: 10.1159/000526386

188. Messinger JC, Suzuki J. Recognizing and reducing the impact of trauma of hospitalization: Considerations for persons who use drugs. J Addict Med. 2022;16(1):7-9. doi: 10.1097/ADM.0000000000000840

189. Long Y, Pan N, Ji S, et al. Distinct brain structural abnormalities in attention-deficit/hyperactivity disorder and substance use disorders: A comparative meta-analysis. Transl Psychiatry. 2022;12(1):368. doi: 10.1038/s41398-022-02130-6

190. Darbinian N, Darbinyan A, Sinard J, et al. Molecular markers in maternal blood exosomes allow early detection of fetal alcohol spectrum disorders. Int J Mol Sci. 2022;24(1):135. doi: 10.3390/ijms24010135

191. Metz VE, Palzes VA, Kline-Simon AH, et al. Substance use disorders among primary care patients screening positive for unhealthy alcohol use. Fam Pract. 2022;39(2):226-233. doi: 10.1093/fampra/cmab171

192. Klein RJ, Gyorda JA, Jacobson NC. Anxiety, depression, and substance experimentation in childhood. PLoS One. 2022;17(5):e0265239. doi: 10.1371/journal.pone.0265239

193. Schnabl B, Arteel GE, Stickel F, et al. Liver specific, systemic and genetic contributors to alcohol-related liver disease progression. Leberspezifische, systemische und genetische Faktoren, die zum Fortschreiten der alkoholbedingten Lebererkrankung beitragen. Z Gastroenterol. 2022;60(1):36-44. doi: 10.1055/a-1714-9330

194. West ML, Sharif S. Cannabis and psychosis. Child Adolesc Psychiatr Clin N Am. 2023;32(1):69-83. doi: 10.1016/j.chc.2022.07.004

195. Gainer DM, Wong C, Embree JA, Sardesh N, Amin A, Lester N. Effects of telehealth on dropout and retention in care among treatment-seeking individuals with substance use disorder: A retrospective cohort study. Subst Use Misuse. 2023;58(4):481-490. doi: 10.1080/10826084.2023.2167496

196. Thakral N, Deutsch-Link S, Singal AK. Therapeutic pipeline in alcohol-associated liver disease. Semin Liver Dis. 2023;43(1):60-76. doi: 10.1055/s-0042-1759614

197. Sambo D, Goldman D. Genetic influences on fetal alcohol spectrum disorder. Genes (Basel). 2023;14(1):195. doi: 10.3390/genes14010195

198. Gómez-Medina C, Melo L, Martí-Aguado D, Bataller R. Subclinical versus advanced forms of alcohol-related liver disease: Need for early detection. Clin Mol Hepatol. 2023;29(1):1-15. doi: 10.3350/cmh.2022.0017

199. Kumar P, Sharma A, Kumar D, Sharma L. Use of spectroscopic methods and their clinical applications in drug abuse: A review. Crit Rev Anal Chem. 2023;53(2):360-373. doi: 10.1080/10408347.2021.1958196

200. Tsai AP, Youngstrom EA, Gadow KD, et al. Diagnostic accuracy of the Child and adolescent symptom inventory (CASI-4R) substance use subscale in detecting substance use disorders in youth. Psychol Assess. 2023;35(2):178-187. doi: 10.1037/pas0001182

201. Patrick ME, Pang YC, Jang BJ, Arterberry BJ, Terry- McElrath YM. Alcohol use disorder symptoms reported during midlife: Results from the monitoring the future study among US adults at modal ages 50, 55, and 60. Subst Use Misuse. 2023;58(3):380-388. doi: 10.1080/10826084.2022.2161826

202. Ishii A, Sato K, Kusakabe K, Kato N, Wada T. Identification and quantitative analysis of 2-fluoromethamphetamine and its metabolites in human urine [published correction appears in J Anal Toxicol. 2022]. J Anal Toxicol. 2023;47(1):59-65. doi: 10.1093/jat/bkac026

203. Greenwald MK, Moses TEH, Lundahl LH, Roehrs TA. Anhedonia modulates benzodiazepine and opioid demand among persons in treatment for opioid use disorder. Front Psychiatry. 2023;14:1103739. doi: 10.3389/fpsyt.2023.1103739

204. Hintze TD, Miller JL, Neely SB, Lim SY, Gupta N, Johnson PN. Characterization of early versus late opioid iatrogenic withdrawal syndrome in critically ill children transitioning from fentanyl -infusions to methadone. J Opioid Manag. 2023;19(1):43-56. doi: 10.5055/jom.2023.0758

205. Dobson MS, Blackhall LJ. Letter to the Editor: Universal screening for substance use disorder in a palliative care clinic: Results and longitudinal outcomes for patients with cancer. J Palliat Med. 2023;26(2):160-161. doi: 10.1089/jpm.2022.0502

206. Sharma K, Ghosh A, Krishnan NC, et al. Digital screening and brief intervention for illicit drug misuse in college students: A mixed methods, pilot, cluster, randomized trial from India. Asian J Psychiatr. 2023;81:103432. doi: 10.1016/j.ajp.2022.103432

207. Henderson EMA, Tappin D, Young D, Favretto D, Mactier H. Assessing maternal alcohol consumption in pregnancy: Does phosphatidylethanol measured from day 5 newborn blood spot cards have any value? An observational, population-based study. Arch Dis Child. 2023;108(1):36-41. doi: 10.1136/archdischild-2022-324394

208. Syrjanen R, Schumann J, Fitzgerald J, et al. The emerging drugs network of Australia - Victoria clinical registry: A state-wide illicit substance surveillance and alert network. Emerg Med Australas. 2023;35(1):82-88. doi: 10.1111/1742-6723.14059

209. Pautrat M, Renard C, Riffault V, et al. Cross-analyzing addiction specialist and patient opinions and experiences about addictive disorder screening in primary care to identify interaction-related obstacles: A qualitative study. Subst Abuse Treat Prev Policy. 2023;18(1):12. doi: 10.1186/s13011-023-00522-5

210. Blum K, Han D, Bowirrat A, et al. Genetic addiction risk and psychological profiling analyses for “preaddiction” severity index. J Pers Med. 2022;12(11):1772. doi: 10.3390/jpm12111772

211. Nutt DJ, Lingford-Hughes A, Erritzoe D, Stokes PR. The dopamine theory of addiction: 40 years of highs and lows. Nat Rev Neurosci. 2015;16(5):305-312. doi: 10.1038/nrn3939

212. Merians AN, Spiller T, Harpaz-Rotem I, Krystal JH, Pietrzak RH. Post-traumatic stress disorder. Med Clin North Am. 2023;107(1):85-99. doi: 10.1016/j.mcna.2022.04.003

213. Zhou J, Friedel M, Rosmarin DH, Pirutinsky S. Internet addiction and the treatment of depression? A prospective naturalistic outcome study. Cyberpsychol Behav Soc Netw. 2023;26(2):121-126. doi: 10.1089/cyber.2022.0184

214. Ray LA, Nieto SJ, Grodin EN. Translational models of addiction phenotypes to advance addiction pharmacotherapy. Ann N Y Acad Sci. 2023;1519(1):118-128. doi: 10.1111/nyas.14929

215. Ghosh A, Sharma N, Noble D, et al. Predictors of treatment completion in an inpatient substance use treatment service in India. J Addict Med. 2023;17(2):e101-e109. doi: 10.1097/ADM.0000000000001076

216. Osińska M, Towpik I, Sanchak Y, Franek E, Śliwczyński A, Walicka M. Cost of surgical treatment of obesity and its impact on healthcare expense-nationwide data from a polish registry. Int J Environ Res Public Health. 2023;20(2):1118. doi: 10.3390/ijerph20021118

217. Lyes M, Yang KH, Castellanos J, Furnish T. Microdosing psilocybin for chronic pain: A case series. Pain. 2023;164(4):698-702. doi: 10.1097/j.pain.0000000000002778

218. Cunningham CO, Starrels JL. Guideline promoting buprenorphine for treatment of chronic pain: Transformative yet underdeveloped. Ann Intern Med. 2023;176(3):419-420. doi: 10.7326/M23-0229

219. Bernal-Sobrino JL, Arias-Horcajadas F, Varela- Rodríguez C, et al. A 3-year retrospective study of the impact of integrating an addiction liaison team into an outpatient alcoholism treatment programme. Alcohol Alcohol. 2023;58(5):515-522. doi: 10.1093/alcalc/agad004

220. Sussman S, Galimov A, Ayala N, Sinclair DL. Web-based evidence on the treatment of behavioral addictions in United States model treatment centers. Eval Health Prof. 2023;46(1):23-29. doi: 10.1177/01632787221130543

221. Natal S, Young CC, Kaur K, et al. Applications of isradipine in human addiction studies: A systematic literature review. Exp Clin Psychopharmacol. 2023;31(2):507-522. doi: 10.1037/pha0000633

222. Rubenis AJ, Nation JA, Katz EC, Arunogiri S. Increasing attendance in addiction treatment with limited resources: A narrative review. J Addict Med. 2023;17(1):13-20. doi: 10.1097/ADM.0000000000001033

223. Husain JM, Cromartie D, Fitzelle-Jones E, Brochier A, Borba CPC, Montalvo C. A qualitative analysis of barriers to opioid agonist treatment for racial/ethnic minoritized populations. J Subst Abuse Treat. 2023;144:108918. doi: 10.1016/j.jsat.2022.108918

224. Salehi M, Abbaspour Z, Molana A, Shahini N. Impulsivity, inhibition, and internet addiction in medical students of North of Iran. Front Psychiatry. 2023;13:1002625. doi: 10.3389/fpsyt.2022.1002625

225. Barnett KB, Amason J, Wagner D, Ray HE. Characteristics of substance-addicted mothers that predict graduation from the family treatment court. J Nurs Scholarsh. 2023;55(3):637-645. doi: 10.1111/jnu.12890

226. Basenach L, Renneberg B, Salbach H, Dreier M, Wölfling K. Systematic reviews and meta-analyses of treatment interventions for Internet use disorders: Critical analysis of the methodical quality according to the PRISMA guidelines. J Behav Addict. 2023;12(1):9-25. doi: 10.1556/2006.2022.00087

227. van der Meer PB, Fuentes JJ, Kaptein AA, et al. Therapeutic effect of psilocybin in addiction: A systematic review. Front Psychiatry. 2023;14:1134454. doi: 10.3389/fpsyt.2023.1134454

228. Cowie ME, Hodgins DC. Contingency management in Canadian addiction treatment: Provider attitudes and use. J Stud Alcohol Drugs. 2023;84(1):89-96. doi: 10.15288/jsad.22-00036

229. Mide M, Arvidson E, Gordh AS. Clinical differences of mild, moderate, and severe gambling disorder in a sample of treatment seeking pathological gamblers in Sweden. J Gambl Stud. 2023;39(3):1129-1153. doi: 10.1007/s10899-022-10183-x

230. Péter L, Paksi B, Magi A, et al. Severity of behavioral addiction symptoms among young adults using non-prescribed sedatives/hypnotics. Addict Behav Rep. 2023;17:100485. doi: 10.1016/j.abrep.2023.100485

231. Tauscher JS, DePue MK, Swank J, Salloum RG. Determinants of preference for telehealth versus in-person treatment for substance use disorders: A discrete choice experiment. J Subst Use Addict Treat. 2023;146:208938. doi: 10.1016/j.josat.2022.208938

232. Lo C, Mane M, Kim JH, et al. Treating addiction with deep brain stimulation: Ethical and legal considerations. Int J Drug Policy. 2023;113:103964. doi: 10.1016/j.drugpo.2023.103964

233. Davidson M, Rashidi N, Hossain MK, Raza A, Nurgali K, Apostolopoulos V. Tryptophan and substance abuse: Mechanisms and impact. Int J Mol Sci. 2023;24(3):2737. doi: 10.3390/ijms24032737

234. Wolfschlag M, Håkansson A. Drug-induced gambling disorder: Epidemiology, neurobiology, and management. Pharmaceut Med. 2023;37(1):37-52. doi: 10.1007/s40290-022-00453-9

235. Brandt L, Hu MC, Liu Y, et al. Risk of experiencing an overdose event for patients undergoing treatment with medication for opioid use disorder. Am J Psychiatry. 202